


30. Steven P, Augustin AJ, Geerling G, et al. Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease. *J Ocul Pharmacol Ther.* 2017;33(9):678–685.
31. Son H-S, Yildirim TM, Khoramnia R, et al. Semi-fluorinated alkane eye drops reduce signs and symptoms of evaporative dry eye disease after cataract surgery. *J Refract Surg.* 2020;36(7):474–480.
32. Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. *Ocul Surf.* 2013;11(4):246–258.
33. Cwiklik L. Tear film lipid layer: a molecular level view. *Biochim Biophys Acta.* 2016;1858(10):2421–2430.
34. Green-Church KB, Butovich I, Willcox M, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Subcommittee on Tear Film Lipids and Lipid-Protein Interactions in Health and Disease. *Invest Ophthalmol Vis Sci.* 2011;52(4):1979–1993.
35. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The International Workshop on Meibomian Gland Dysfunction: report of the definition and classification subcommittee. *Invest Ophthalmol Vis Sci.* 2011;52(4):1930–1937.
36. Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. *Ocul Surf.* 2017;15(3):511–538.
37. Troiano P, Monaco G. Effect of hypotonic 0.4% hyaluronic acid drops in dry eye patients: a cross-over study. *Cornea.* 2008;27(10):1126–1130.
38. Aragona P, Di Stefano G, Ferreri F, et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients. *Br J Ophthalmol.* 2002;86(8):879–884.

## Pictures & Perspectives



### Systemic Treatment Reduces Von-Hippel-Lindau–Associated Retinal Capillary Hemangioblastoma

A 24-year-old man with Von-Hippel-Lindau syndrome and central nervous system (CNS) hemangioblastomas was found to have multiple leaking retinal capillary hemangioblastomas in the superotemporal periphery of the left eye (A). Systemic treatment was initiated with Belzutifan, a hypoxia-inducible factor-2 $\alpha$  inhibitor. There was marked improvement in the engorgement and tortuosity of the feeding arterioles and draining veins, and a reduction in the number and size of the retinal capillary and CNS hemangioblastomas after 6 months of treatment (B) (Magnified version of Fig A–B is available online at [www.aaojournal.org](http://www.aaojournal.org)).

AARON M. FAIRBANKS, MD

SANDRA HOYEK, MD

NIMESH A. PATEL, MD

Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts

## Footnotes and Disclosures

Supported by the Retina Innovation Fund, Massachusetts Eye and Ear, Boston, Massachusetts (to N.A.P.).